|
1 Chen J, Smith L. Retinopathy of Prematurity [J]. Angiogenesis, 2007,10:133-140.
|
|
2 Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity [J]. Ophthalmic Surg Lasers Imaging, 2007,38:233-237.
|
|
3 Connor K, SanGiovanni J, Lofqvist C, et al. Increased dietary intake of v-3-polyunsaturated fatty acids reduces pathological angiogenesis[J]. Nat Med,2007, 13:868-873.
|
|
4 Suk K, Dunbar J, Liu A, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: A multiple regression model[J]. J AAPOS,2008,12: 233-238.
|
|
5 Lofqvist C, Chen J, Connor K, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth[J]. PNAS, 2007, 104: 10589-10594.
|
|
6 Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants:Relationship to retinopathy of prematurity [J]. Br J Ophthalmol, 2008, 92:689-693.
|
|
7 Huang LN, Zhang GM, Wu BQ. Retinopathy of prematurity [M]. Guangzhou: Guangdong Science and Technology Press, 2007, 32-36. [黄丽娜，张国明，吴本清.早产儿视网膜病变[M]. 广州：广东科学技术出版社，2007,32-36.]
|
|
8 Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration [J]. N Engl J Med 2006,355:1419-1431.
|
|
9 Ueta T, Yanagi Y, Tamaki Y, et al. Cerebrovascular accidents in ranibizumab[J]. Ophthalmology, 2009, 116:362.
|
|
10 Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity[J]. Ophthalmic Surg Lasers Imag, 2007, 38:233-237.
|
|
11 Lalwani G, Berrocal A, Murray T, et al. Off-label use of intravitreal bevacizumab ( avastin) for salvage treatment in progressive threshold retinopathy of prematurity [ J]. Retina, 2008, 28:S13-S18.
|
|
12 Kusake S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study[J]. Br J Ophthalmol, 2008, 92:1450-1455.
|
|
13 Sonmez K, Drenser K, Capone A,et al. Vitreous levels of stromal cellderived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity [ J]. Ophthalmology, 2008, 115:1065-1070.
|
|
14 Liu G, Wu JL, Mu DZ. Treatment progress of retinopathy of prematurity [J/CD]. Chin J Obstet Gynecol Pediatr (Electron Ed), 2010, 6(3): 219-222.[刘罡，伍金林，母得志，等.早产儿视网膜病的治疗进展[J/CD].中华妇幼临床医学杂志：电子版，2010，6(3)：219-222.]
|
|
15 Honda S, Hirabayashi H, Tsukahara Y,et al. Acute contraction of the proliferative membrane after intravitreal injection of bevacizumab for advanced retinopathy of prematurity [J]. Graefes Arch Clin Exp Ophthalmol, 2008, 246:1061-1063.
|
|
16 Mintz-Hittner H, Kuffel R. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone Ⅱ [J]. Retina, 2008, 28:831-838.
|
|
17 Quiroz-Mercado H, Martinez-Castellanos M, Hernandez-Rojas M, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity[J]. Retina, 2008, 28: s19-s25.
|
|
18 Kim MJ, Kim S-J, Yu YS. The risk for retinal detachment associated with hemorrhages pre and postlaser treatment in retinopathy of prematurity[J]. Retina,2008, 28: 1451-1457.
|
|
19 Kong L, Mintz-Hittner H, Penland R, et al. Intravitreal bevacizumab as antivascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study [J]. Arch Ophthalmol, 2008, 126:1161-1163.
|
|
20 Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model [J]. Am J Pathol, 1994,145:574-584.
|
|
21 Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab (avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity [J]. Indian J Ophthalmol, 2007,55:75-76.
|
|
22 McLoone E, O'Keefe M, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: Results of goldman Perimetry at a mean age of 11 years[J]. J Pediatr Ophthalmol Strabismus, 2007, 144:170-173.
|
|
23 Sears JE. Anti-vascular endothelial growth factor and retinopathy of prematurity[J]. B J Ophrthalmol, 2008,92: 14-38.
|